Protein kinase C (PKC) has a key role in the signal transduction machinery involved in the regulation of amyloid precursor protein (APP) metabolism. Direct and indirect receptor-mediated activation of PKC has been shown to increase the release of soluble APP (sAPPa) and reduce the secretion of b-amyloid peptides. Experimental evidence suggests that specific isoforms of PKC, such as PKCa and PKCe, are involved in the regulation of APP metabolism. In this study, we characterized the role of PKCa in the regulated secretion of APP using wild-type SH-SY5Y neuroblastoma cells and cells transfected with a plasmid expressing PKCa antisense cDNA. Cells expressing antisense PKCa secrete less sAPPa in response to phorbol esters. In contrast, carbachol increases the secretion of sAPPa to similar levels in wild-type cells and in cells transfected with antisense PKCa by acting on APP metabolism through an indirect pathway partially involving the activation of PKC. These results suggest that the direct PKC-dependent activation of the APP secretory pathway is compromised by reduced PKCa expression and a specific role of this isoform in these mechanisms. On the other hand, indirect pathways that are also partially dependent on the mitogen-activated protein kinase signal transduction mechanism remain unaffected and constitute a redundant, compensatory mechanism within the APP secretory pathway.
Introduction
The metabolic fate of the amyloid precursor protein (APP) is one of the key factors in the pathogenesis of Alzheimer's disease (AD). 1 The routes of APP metabolism result in different pathways, leading to proteolytic processing of the precursor by at least three proteolytic activities that have been more closely characterized in recent years. [2] [3] [4] [5] At the cell surface or in a secretory vesicle in its immediate proximity, a protease named 'a secretase' cleaves APP in the extracellular domain and releases the ectodomain (sAPPa or soluble APPa) into the extracellular space. This proteolytic cleavage constitutes the non-amyloidogenic pathway because it occurs within the b-amyloid (Ab) sequence, thereby preventing the formation of amyloidogenic fragments. The Ab peptide is formed and secreted as a physiological product of cell metabolism as a product of 'b-' and 'g-secretase' that cleave at the N and C termini of Ab respectively (reviewed by Mills and Reiner 6 and Racchi and Govoni 7 ). Both pathways are physiologically present in virtually all cell types and result in constitutive secretion of sAPPa and Ab. In normal cellular processing, APP can be committed either to the non-amyloidogenic secretory pathway or to Ab generating pathways. The choice between these two pathways appears to be a highly regulated process that can be influenced by extracellular signals and intracellular second messengers. 7 Several reports suggest a pivotal role of protein kinase C (PKC) in routing APP between the two different pathways: phorbol ester activation of PKC increases a-secretase-mediated sAPP secretion and reduces cellular secretion of Ab peptide. 6, 7 The pivotal involvement of PKC in the regulated secretory processing of APP assumes particular importance in the pathogenesis of AD because several authors have demonstrated that both PKC activity and amount are reduced in AD brain. 8, 9 These data led to the hypothesis that the observed impairment of the PKC signal transduction pathway may participate in the dysregulation of APP processing in AD patients, leading to the deposition of Ab peptide. In addition, data from a number of laboratories, including ours, have demonstrated a decreased PKC activity in sporadic AD fibroblasts. 10 We also observed an increase of the Kd (dissociation constant) for phorbol ester binding in the cytosolic fraction of AD fibroblasts, which suggested an alteration in the characteristics of the kinase. Subsequently, the described changes in PKC were correlated to a specific 30% reduction in PKCa immunoreactivity. 11 In fibroblasts from sporadic AD patients we have demonstrated a reduced basal sAPP release from AD cells, suggesting the presence of a constitutive defect in the secretory mechanisms of the amyloid precursor. In addition, we demonstrated that AD cells have a lower sensitivity to stimulation of release of sAPPa by phorbol ester with an EC 50 two-fold higher than control fibroblasts. This result indicates a fundamental defect in the mechanisms supporting PKC-mediated sAPPa secretion. a-secretase pathway in AD fibroblasts is defective because of a reduced PKCa, leading to a possible diversion of APP metabolism towards the amyloidogenic pathway.
Although PKC is suggested as a central mechanism regulating sAPPa release, a number of intracellular signalling pathways interact to form a complex network. In fact, it has been demonstrated that in addition to the direct activation of PKC, the metabolic processing of APP can be stimulated by a variety of ligands acting on their receptors. Among these, acetylcholine was the first to be described in a key paper in 1992 by Nitsch et al, 12 which suggested that cholinergic agonists could also affect AD pathogenesis by modulating APP metabolism. Downstream of cholinergic receptors and most other G-proteincoupled receptors, the activation of PKC, the mitogen-activated protein kinase (MAP-K) cascade, and the activation of unspecified Tyr kinases have been suggested 13, 14 as either connected or independent events. There are at least three major signal transduction pathways involved in receptor-mediated APP processing, and the role of individual PKC isoforms in such complex interactions has not yet been addressed.
The goal of the present study was to characterize the role of PKC isoforms in the regulated secretion of APP. Because of the data on sporadic AD fibroblasts, we wanted to study the direct activation of PKC in a system where the chronic down-regulation of PKCa could be reproduced to determine whether a specific isoform of PKC is directly responsible for the activation of APP secretion. Furthermore, we sought to determine whether the specific PKCa isoform is involved in the complex interaction of signalling pathways downstream of cholinergic receptors leading to APP proteolytic processing.
Materials and methods

Materials
All culture media, supplements, and fetal calf serum (FCS) were obtained from Gibco Life Technologies (Paisley, Scotland, UK). Electrophoresis reagents were obtained from Bio-Rad (Hercules, CA, USA). All other reagents were of the highest grade available and were purchased from Sigma Chemical Co. (St Louis, MO, USA), unless otherwise indicated. Phorbol 12-myristate 13-acetate (PMA), GF109203X (Calbiochem, Darmstadt, Germany), PD98059 (Alexis Biochemicals, San Diego, CA, USA), and Gö 6976 (Calbiochem, Darmstadt, Germany) were dissolved in dimethyl sulfoxide (DMSO) and stored at À201C. Stocks were diluted in serum-free medium prior to the experiments. Carbachol and neomycin were dissolved and diluted to working concentration in serum-free minimum essential medium (MEM) at the moment of use.
Cell cultures and experimental treatments SH-SY5Y neuroblastoma cells were cultured in Eagle's MEM supplemented with 10% FCS, penicillin/streptomycin, non-essential amino acids, and sodium pyruvate (1 mM) at 371C in 5% CO 2 /95% air. The cell line with stable antisense down-regulation of PKCa was provided by Dr Thomas B Shea (McLean Hospital, Boston, MA, USA) and was grown in the same medium with the addition of the selecting agent G418 (Gibco Life Technologies, Paisley, Scotland, UK) at 400 mg/ml. For the experiments, 4 Â 10 6 cells were seeded on 60 mm dishes and cultured for 24 h. Prior to the experiment, confluent monolayers of cells were washed twice with phosphate-buffered saline (PBS) and once with serum-free culture medium. Experimental treatments for the detection of sAPPa released into the conditioned medium were performed in serum-free MEM with incubation for 2 h at 371C. Experiments for the detection of activated mitogen-activated protein kinase (MAP kinase) were performed with incubations of 10 min. In all experiments involving the use of inhibitors such as neomycin, GF109203X, PD98059, or Gö 6976, the compounds were preincubated for 10-30 min prior to the addition of PMA or carbachol.
Immunodetection of sAPPa and PKC Conditioned medium was collected after 2 h of incubation and centrifuged at 13 000 g for 5 min to remove detached cells and debris. Proteins in the medium were quantitatively precipitated by the deoxycholate/trichloroacetic acid procedure as previously described. 11 Cell monolayers were washed twice with ice-cold PBS and lysed on the tissue culture dish by the addition of ice-cold lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% TritonX-100). An aliquot of the cell lysate was used for protein analysis with the Bio-Rad Bradford kit for protein quantification. Normalization of protein loading on each blot was obtained by loading a volume of sample of conditioned medium standardized to total cell lysate protein concentration. Proteins were subjected to sodium dodecylsulphatepolyacrylamide gel electrophoresis (SDS-PAGE) (10%) and then transferred onto PVDF membrane (DuPont NEN, Boston, MA, USA). The membrane was blocked for 1 h with 10% non-fat dry milk in Trisbuffered saline (TBS) containing 1% Tween 20 (TBST). Membranes were immunoblotted with the antibodies 22C11 or 6E10 (at least once for each set of experiments) (Chemicon-Prodotti Gianni, Milano, Italy), which gave rise to the same pattern of bands. The detection was carried out by incubation with horseradish peroxidase conjugated goat anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburgh, MD, USA) for 1 h. The blots were then washed extensively and sAPPa visualized using enhanced chemiluminescent methods (Pierce, Rockford, IL, USA). For the detection of PKC, cells were homogenized in a buffer constituted of 20 mM Tris/HCl pH 7.5, 2 mM EDTA, 0.2 mM phenylmethylsulfonylfluoride, 20 mg/ml leupeptin and 25 mg/ml aprotinin, and 0.5% TritonX-100. Proteins were measured as described earlier and subjected to Western blot analysis Protein kinase Ca in APP processing M Racchi et al with the method indicated previously using isoform specific monoclonal antibodies from Transduction Laboratories (Lexington, KY, USA) and from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blot for extracellular signal-regulated protein kinase (ERK) phosphorylation SH-SY5Y cells were cultured in serum-free medium overnight before stimulation with agonists for 10 min with or without preincubation for 30 min with PD-98059. After stimulation, the cells were lysed in lysis buffer (62.5 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT, 0.1% bromphenol blue). Cell lysates were boiled for 5 min and then centrifuged at 13 000 rpm for 5 min. Lysate aliquots of 25 ml were loaded on 10% SDS-PAGE gels and the separated proteins were then subjected to electrophoretic transfer to PVDF membranes. Blots were probed with either a rabbit polyclonal antibody specific for ERK (p44/p42 MAP kinase) (New England Biolabs, Beverly, MA, USA) or a monoclonal antibody for phosphorylated ERK (phospho-44/42 MAP kinase) (Upstate Biotec Inc., Lake Placid, NY, USA).
Densitometry and statistics
Analysis of Western blot images was performed by calculating the relative intensity of the immunoreactive bands after acquisition of the blot image through a Nikon CCD video camera module and analysis by means of the Image 1.47. program (Wayne Rasband, NIH, Research Service Branch, Nimh, Bethesda, MD, USA). The relative densities of the bands were expressed as arbitrary units and normalized to data obtained from control samples run under the sample conditions. Controls were processed in parallel with stimulated samples and always included in the same blot. Preliminary experiments with serial dilutions of secreted protein allowed the determination of an optimal linear range for chemiluminescence reaction. Statistical analysis was made by the one-way analysis of variance test followed, when significant, by the two-tailed Student's t-test or multiple comparison test, where appropriate; a P value o0.05 was considered significant.
Results
For our investigation, we chose to use the human neuroblastoma cell line SH-SY5Y as the cellular model. We have obtained a cell line stably expressing the cDNA for PKCa in the antisense orientation from Dr TB Shea (McLean Hospital, Boston, MA, USA). 15 We refer to this line as SYa4 and compare it to parental SH-SY5Y cells, which we refer to as SYwt. Western blot analysis (Figure 1 ) confirmed the specific down-regulation of the target isoform and the maintenance of the expression levels for other isoforms including PKCe and PKCd, in accordance with the pattern shown in previous experiments using these cell lines. 15, 16 The cellular model was also chosen because SH-SY5Y cells express muscarinic receptors of the m1 and m3 subtype, 17, 18 and this characteristic makes the cell line suitable for the characterization of PKC-dependent and receptormediated APP metabolism without further manipulation. These cells secrete sAPPa, which can be detected by either the 22C11 or 6E10 monoclonal antibodies, with the same SDS gel band pattern. The sAPPa band appears as a doublet with an apparent molecular weight of 100-120 kDa (Figure 2) , 19 with a pattern that reflects the expression of the three major isoforms of APP. These isoforms include mRNAs containing exon 7 (encoding the KPI domain) and exon 8, isoforms Protein kinase Ca in APP processing M Racchi et al containing only exon 7, and APP mRNAs where both exons are spliced out. 20 The cells respond to phorbol esters and carbachol by releasing sAPPa ranging two to three-fold above basal levels (Figure 2) . Furthermore, following simultaneous treatment with carbachol and phorbol ester, these cells secrete sAPPa to an extent that is less than the net sum of the independent effects of these two compounds. This decreased secretion as a result of combined treatment suggests that the two pathways may be at least partially independent of each other (Figure 2 ). The effect of PKCa down-regulation on phorbol-ester-stimulated APP metabolism was examined by treating SYwt cells and SYa4 cells for 2 h with increasing concentrations of PMA. As shown in Figure 3 , both cell lines responded to PMA-driven activation of PKC by a concentration-dependent increase in the release of sAPPa, but with significantly different patterns. In particular, the SYwt cell line responded with a significant increase of sAPPa release at low concentrations of the activator. A 10 nM concentration of PMA is sufficient to elicit an approximately two-fold increase in the basal release of sAPPa. The effect of phorbol ester activation reached a maximum at 100 nM with an increase of approximately 2.5-fold of basal release and remained substantially equivalent at higher concentrations (1 mM PMA). Cells with down-regulated expression of PKCa remained silent at low concentrations of PMA (10 nM) while responding at increasing concentrations to a lesser extent than SYwt. At 1 mM PMA the average increase of sAPPa released remained lower than that of SYwt cells; however, differences were not significant.
Treatment of SYwt cells with increasing concentrations of carbachol results in a concentration-dependent increase in sAPPa release with a maximally effective concentration of 1 mM (Figure 4) . The same treatment applied to SYa4 cells produced similar results. In contrast to the findings with PMA stimulation, the intracellular pathways linking cholinergic receptors to sAPPa release were not affected by PKCa down-regulation.
The pathway downstream of muscarinic receptors involved in the regulation of APP metabolism is complex, and some authors suggest that it involves the activation of ERKs and the MAP-kinase pathway. 13 Stimulation of SYwt and SYa4 with carbachol resulted in equally increased ERK phosphorylation (Figure 5a ) in the two cell lines. Since it has been suggested that ERKs are involved in carbacholinduced sAPPa release, we blocked ERKs activation by preincubation of the cells with PD98059, a wellknown MEK inhibitor. Blockade of ERKs phosphorylation (Figure 5a ) resulted in partial inhibition of carbachol-mediated sAPPa release in both cell lines (Figure 5b) . Finally, the signalling pathway involved in carbachol-mediated sAPPa release depends in part on the activation of phospholipase C (PLC) as indicated by the fact that the effect is partially inhibited by pretreatment with the PLC inhibitor neomycin 21 ( Figure 6a ). This would include the involvement of either Ca 2+ or inositol turnover. Carbachol promotes the non-amyloidogenic metabolism of APP similarly in wild-type cells and in antisense transfected neuroblastoma cells. Cells were incubated for 2 h with serum-free medium alone or increasing concentrations of CCh (10 mM, 100 mM, 1 mM). Proteins released into the conditioned media were collected and subjected to Western blot analysis for sAPPa. The blots were subsequently quantified by densitometry as described in the 'Materials and methods' section. Data are expressed as a percentage of basal release and are representative of three to four independent experiments.
Protein kinase Ca in APP processing M Racchi et al
Pretreatment of the cells (SYwt) with the PKC inhibitor GF109203X, which is not selective for PKC isoforms, reduced the stimulatory effect of 1 mM carbachol by an average of 40% (Figure 6b ). However, selective inhibition of PKCa using the compound Gö 6976, which is selective for Ca 2+ -dependent PKC isoforms, had no significant effect on the stimulation of sAPPa release by carbachol. This result suggests that the limited involvement of PKC in cholinergic activation of sAPPa release is not dependent on PKCa.
Discussion
We demonstrate here that PKCa is specifically involved in phorbol ester-induced APP metabolism and that its contribution is specific for direct PKCmediated pathways. Whereas down-regulation of PKCa can significantly impair phorbol-ester-induced sAPPa release from SH-SY5Y cells, the down-regulation of the kinase isoform does not affect carbacholmediated sAPPa release.
There are multiple intracellular second messengers that contribute to the regulation of APP metabolism and they have extremely complex interactions. 7 PKC was one of the first signal transduction related molecules to be implicated in the regulation of APP metabolism. 6, 7 The extensive studies on regulation of APP processing by PKC suggest that the Ab forming amyloidogenic pathway and the non-amyloidogenic a-secretase pathway are balanced, the latter being activated by PKC. Although this simple view of APP metabolism may not fully reflect the complexity of the system, 22 PKC-defective pathways have been described in peripheral tissues of sporadic AD patients 10, 23 and these defects have been associated with aberrant APP processing. 11 The central role of PKC in APP metabolism is therefore also connected to the fact that defective PKC is one of the most consistent findings in AD brain and peripheral tissues. 8, 24 In our previous work, we found that the defective APP metabolism described in AD fibroblasts is paralleled by a defective PKC activity and, in particular, PKCa was found to be reduced in AD fibroblasts. 11 The average reduction in the expression of PKCa protein in AD fibroblasts was 30%, similar to the levels of down-regulation of approximately 40% observed in the SYa4 neuroblastoma cellular model used in this study.
We show here that the phorbol ester-stimulated secretion of sAPPa in SYa4 cells is defective. Interestingly, the pattern of response to phorbol ester shown by the SYa4 cell line is remarkably similar to that previously observed with AD fibroblasts. 11 In particular, the cells seem to be totally unresponsive to low concentrations of phorbol ester (10 nM) while SYwt cells respond to phorbol ester treatment at the same concentration with a two-fold increase of sAPPa released above basal secretion. The fibroblast data suggest that these cells may have lost a high-affinity binding site for phorbol esters and that PKCa is responsible for the effect. Among the different kinase Carbachol-mediated sAPPa release in the presence of PLC and PKC inhibitors. SH-SY5Y (SYwt) cells were treated for 2 h with 1 mM carbachol following pretreatment with vehicle and/or 100 mM neomycin for 10 min (panel (a) ). SH-SY5Y (SYwt) cells were treated for 2 h with 1 mM carbachol following pretreatment for 30 min with vehicle with and without 2.5 mM GF109203X (a nonselective PKC inhibitor) or 2 mM Gö 6976 (a selective inhibitor of PKC a, b and g isoforms) (panel (b) ). The figure shows a representative immunoblot (out of three independent experiments).
isoforms, PKCa and the other calcium-dependent isoforms have the highest affinity for phorbol esters, 25 of the same order of magnitude of the lowest concentration used. Higher concentrations are necessary to activate other kinase isoforms that may be novel PKCs. In our current experiments using SYa4 cells as well as in published experiments using AD fibroblasts, a significant secretory response was elicited only at 100 nM phorbol ester. The current data indicate that PKCa is specifically involved in the phorbol-ester-mediated APP processing to the extent of physiological levels of direct activators. Higher concentrations would drive the activation of other kinases and possibly overcome the defect of a single isoform.
Many results have been reported in the literature that suggest a role for PKCa and other isoforms in the regulated secretion of APP. Initially, it was demonstrated that over-expression of PKCa in Swiss 3T3 fibroblasts increased the sensitivity of APP processing to phorbol esters. 26 Subsequently, other investigators in various experimental systems involving either pharmacological down-regulation or inhibition of PKCa 27, 28 or over-expression of PKCa 29 have indicated that PKCa plays a significant role in APP metabolism. We provide here for the first time a demonstration of the role of PKCa in a system that has been manipulated to reproduce the long-term downregulation of PKCa described in fibroblasts from AD patients.
Other authors pointed more specifically to the role of another isoform, PKCe. Kinouchi et al showed that over-expression of PKCe also induces an increase of sAPPa. 29 Other strategies pursuing the inhibition of PKCe provided evidence of a role of that isoform in APP processing. The over-expression of the PKCe V1 region, which binds specifically to the receptor for activated C-kinase (RACK), blocked phorbol-esterinduced enhancement of APPa secretion. 30 However, that result was obtained in B103 neuroblastoma cells over-expressing APP. Those cells reportedly do not express endogenous APP and therefore may not include the completely physiological machinery for APP processing. A more recent indication on the role of PKCe was reported by Zhu et al, 31 who showed that expression of a peptide inhibitor of PKCe reduced phorbol-ester-mediated sAPP release. This result ruled out the involvement of PKCa because of the ineffectiveness of Gö6976, which is a specific inhibitor of PKCa, b, and g isoforms.
The purpose of our study was to investigate the role of PKCa in the regulated secretory processing of APP. We studied the involvement of this kinase isoform within the complex intracellular signalling pathway 7 involved in APP processing, and we focussed on a receptor-mediated pathway that, according to the literature, partially involves PKC activation. Our experiments with phorbol ester established that PKCa is significantly involved in the PKC pathway. The degree of activation of the pathway by phorbol esters depends on the concentration used and can influence the pattern of kinase isoforms involved, so we turned our attention to the cholinergic receptormediated APP processing. The first study indicating that APP processing could be modulated by cholinergic receptors was conducted in HEK293 cells overexpressing muscarinic m1 receptors. 12 This result was followed by multiple confirmations. 6, 7 The demonstration that cholinesterase inhibitors studied for AD therapy also induced sAPP release by an indirect cholinergic mechanism further substantiated this result. 20 Stimulation of G-protein-coupled receptors by neurotransmitters regulates APP processing by PKC-dependent signalling pathways. In particular, the cholinergic receptor stimulation of sAPP release is blocked by staurosporine 12 and GF109203X. 14, 20 We show here that both cell lines respond equally to carbachol in spite of the defective PKCa in the SYa4 cell line. This result suggests that the involvement of PKCa in the carbachol-regulated APP processing is not significant or at least that redundant signalling pathways are activated that can bypass the defective kinase. Although PKC activation can undoubtedly stimulate sAPPa release, this is not the only mechanism activated downstream of the cholinergic receptor that is linked to the activation of APP processing. This has been clear since it was shown that the inhibition of APP secretion by GF109203X was not complete, 14 and thus it was suggested that other kinase pathways may be involved. In particular, Slack et al suggested the involvement of a Tyr kinase 14 together with the involvement of a MAP-kinase pathway. 13 The signalling pathways downstream of the m3 muscarinic receptor clearly involve both PKC-dependent and -independent mechanisms coupled to the activation of the MAP-kinase pathway. 32 However, for the latter mechanism as it relates to APP metabolism, there are contrasting reports. Desdouit-Magnen et al 33 were not able to demonstrate a block of carbacholmediated sAPPa release in PC12-M1 cells treated with the MEK inhibitor PD98059. On the same cellular model, however, Haring et al 13 showed a significant inhibition of carbachol-mediated sAPPa release by PD98059. In our system using SH-SY5Y, which endogenously expresses both APP and m1/m3 muscarinic receptors, we observed a reduction of carbachol-mediated sAPPa release by PD98059, suggesting at least a partial involvement of MAP-kinase pathways. Interestingly, no differences in the activation of the MAP-kinase system were detected between SYa4 and SYwt cells, suggesting that the recruitment of ERKs was not affected by the specific downregulation of PKCa. This also suggests that although MAP kinases can be activated by PKC following phorbol ester treatment 33, 34 and that such activation may promote sAPPa release, PKCa is not the kinase isoform involved. This is consistent with data in the literature that suggests that PKCe is the only kinase isoform in SK-N-BE2(C) neuroblastoma cells involved in MAP-kinase activation upon m3 muscarinic receptor challenge. 35 Protein kinase Ca in APP processing M Racchi et al A further demonstration that PKCa is not significantly involved in the pathway downstream of cholinergic receptors comes from the experiments with neomycin and with selective PKC inhibitors. Neomycin is a phosphatidylinositide-specific PLC inhibitor 21 that partially blocks the effect of carbachol on sAPPa release in SYwt cells. The blockade of PLC would reduce the contribution of Ca 2+ and phosphatidylinositol, thus blocking the contribution of cofactors for the activation of PKC. As described before, the inhibition of carbachol-mediated sAPPa release can be partially obtained, with the PKC inhibitor GF109203X, 14, 20 which is not selective for PKC isoforms. We show here that Gö 6976, the specific inhibitor of Ca 2+ -dependent PKC isoforms a, b, and g, did not block the effect of carbachol, thus conclusively demonstrating that PKCa is not involved in receptor-mediated sAPPa release. Among the other isoforms present in SH-SY5Y cells and because of data in the literature concerning both APP metabolism [29] [30] [31] and the pharmacology of muscarinic receptor signalling, 35 we favor the specific involvement of PKCe and investigations of this hypothesis are under way.
The description of the role of PKCa here is relative to the data obtained with cholinergic receptors, and other receptor-mediated effects (glutamate, serotonin) have to be investigated specifically. These data indicate that multiple isoforms of PKC are differentially involved and each can specifically contribute to the complexity of the intracellular pathways regulating APP proteolytic metabolism. The data also suggest that the defects observed in fibroblasts from affected patients may be tissue specific according to the blend of expressed kinases and may be largely compensated by the described redundant receptor-mediated mechanisms controlling APP metabolism. On the other hand, these subtle defects may decrease the functional reserve of the system, leading with time or in the presence of additional damage to the unbalancing of APP metabolism toward b-and g-secretase pathways.
